{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:55:00Z","timestamp":1767138900868,"version":"build-2238731810"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00120-022-01831-6","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T08:04:43Z","timestamp":1651046683000},"page":"537-551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["G-CSF zur Prophylaxe der Neutropenie und der febrilen Neutropenie, An\u00e4mie bei Krebserkrankung","G-CSF for prophylaxis of neutropenia and febrile neutropenia, anemia in cancer"],"prefix":"10.1007","volume":"61","author":[{"given":"Hartmut","family":"Link","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"1831_CR1","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1056\/NEJM198806023182202","volume":"318","author":"JL Gabrilove","year":"1988","unstructured":"Gabrilove\u00a0JL, Jakubowski\u00a0A, Scher\u00a0H, Sternberg\u00a0C, Wong\u00a0G, Grous\u00a0J et al (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N\u00a0Engl J Med 318:1414\u20131422","journal-title":"N Engl J Med."},{"key":"1831_CR2","unstructured":"(2017) CTEP: common terminology criteria for adverse events (CTCAE) v5.0., https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Zugegriffen: 26.04.2022"},{"issue":"11","key":"1831_CR3","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s00277-017-3098-3","volume":"96","author":"WJ Heinz","year":"2017","unstructured":"Heinz\u00a0WJ, Buchheidt\u00a0D, Christopeit\u00a0M, von Lilienfeld-Toal\u00a0M, Cornely\u00a0OA, Einsele\u00a0H et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96(11):1775\u20131792. https:\/\/doi.org\/10.1007\/s00277-017-3098-3","journal-title":"Ann Hematol"},{"issue":"10","key":"1831_CR4","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/jco.2001.19.10.2638","volume":"19","author":"CN Sternberg","year":"2001","unstructured":"Sternberg\u00a0CN, Mulder\u00a0PH, Schornagel\u00a0JH, Th\u00e9odore\u00a0C, Fossa\u00a0SD, Oosterom ATv et al (2001) Randomized phase III trial of high\u2013dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol no. 30924. J\u00a0Clin Oncol 19(10):2638\u20132646. https:\/\/doi.org\/10.1200\/jco.2001.19.10.2638","journal-title":"J Clin Oncol"},{"issue":"1","key":"1831_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","volume":"42","author":"CN Sternberg","year":"2006","unstructured":"Sternberg\u00a0CN, de Mulder\u00a0P, Schornagel\u00a0JH, Theodore\u00a0C, Fossa\u00a0SD, van Oosterom\u00a0AT et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M\u2011VAC chemotherapy and G\u2011CSF versus classic M\u2011VAC in advanced urothelial tract tumours. Eur J Cancer 42(1):50\u201354. https:\/\/doi.org\/10.1016\/j.ejca.2005.08.032","journal-title":"Eur J Cancer"},{"issue":"1","key":"1831_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/s1470-2045(14)71160-x.","volume":"16","author":"CN Sternberg","year":"2015","unstructured":"Sternberg\u00a0CN, Skoneczna\u00a0I, Kerst\u00a0JM, Albers\u00a0P, Fossa\u00a0SD, Agerbaek\u00a0M et al (2015) Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16(1):76\u201386. https:\/\/doi.org\/10.1016\/s1470-2045(14)71160-x","journal-title":"Lancet Oncol"},{"key":"1831_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02051","author":"C Pfister","year":"2022","unstructured":"Pfister\u00a0C, Gravis\u00a0G, Fl\u00e9chon\u00a0A, Chevreau\u00a0C, Mahammedi\u00a0H, Laguerre\u00a0B et\u00a0al (2022) Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/jco.21.02051","journal-title":"J\u00a0Clin Oncol."},{"issue":"10","key":"1831_CR8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/jco.2011.38.6979","volume":"30","author":"j Bellmunt","year":"2012","unstructured":"Bellmunt , von der Maase\u00a0H, Mead\u00a0GM, Skoneczna\u00a0I, De Santis\u00a0M, Daugaard\u00a0G et\u00a0al (2012) Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J\u00a0Clin Oncol 30(10):1107\u20131113. https:\/\/doi.org\/10.1200\/jco.2011.38.6979","journal-title":"J Clin Oncol"},{"issue":"17","key":"1831_CR9","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/jco.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase\u00a0H, Hansen\u00a0SW, Roberts\u00a0JT, Dogliotti\u00a0L, Oliver\u00a0T, Moore\u00a0MJ et\u00a0al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a\u00a0large, randomized, multinational, multicenter, phase III study. J\u00a0Clin Oncol 18(17):3068\u20133077. https:\/\/doi.org\/10.1200\/jco.2000.18.17.3068","journal-title":"J Clin Oncol"},{"issue":"28","key":"1831_CR10","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/jco.2016.72.1068","volume":"35","author":"S Oudard","year":"2017","unstructured":"Oudard\u00a0S, Fizazi\u00a0K, Sengel\u00f8v\u00a0L, Daugaard\u00a0G, Saad\u00a0F, Hansen\u00a0S et al (2017) Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J\u00a0Clin Oncol 35(28):3189\u20133197. https:\/\/doi.org\/10.1200\/jco.2016.72.1068","journal-title":"J Clin Oncol"},{"issue":"2","key":"1831_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s1470-2045(12)70537-5","volume":"14","author":"PL Kellokumpu-Lehtinen","year":"2013","unstructured":"Kellokumpu-Lehtinen\u00a0PL, Harmenberg\u00a0U, Joensuu\u00a0T, McDermott\u00a0R, Hervonen\u00a0P, Ginman\u00a0C et al (2013) 2\u2011Weekly versus 3\u2011weekly docetaxel to treat castration-resistant advanced prostate cancer: a\u00a0randomised, phase 3 trial. Lancet Oncol 14(2):117\u2013124. https:\/\/doi.org\/10.1016\/s1470-2045(12)70537-5","journal-title":"Lancet Oncol"},{"issue":"28","key":"1831_CR12","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/jco.2016.72.1076","volume":"35","author":"M Eisenberger","year":"2017","unstructured":"Eisenberger\u00a0M, Hardy-Bessard\u00a0AC, Kim\u00a0CS, G\u00e9czi\u00a0L, Ford\u00a0D, Mourey\u00a0L et al (2017) Phase III study comparing a\u00a0reduced dose of cabazitaxel (20\u202fmg\/m(2)) and the currently approved dose (25\u202fmg\/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J\u00a0Clin Oncol 35(28):3198\u20133206. https:\/\/doi.org\/10.1200\/jco.2016.72.1076","journal-title":"J Clin Oncol"},{"issue":"27","key":"1831_CR13","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1200\/JCO.2005.19.638","volume":"23","author":"GV Kondagunta","year":"2005","unstructured":"Kondagunta\u00a0GV, Bacik\u00a0J, Donadio\u00a0A, Bajorin\u00a0D, Marion\u00a0S, Sheinfeld\u00a0J et al (2005) Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J\u00a0Clin Oncol 23(27):6549\u20136555. https:\/\/doi.org\/10.1200\/JCO.2005.19.638","journal-title":"J Clin Oncol"},{"issue":"11","key":"1831_CR14","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1200\/jco.1999.17.11.3450","volume":"17","author":"C Bokemeyer","year":"1999","unstructured":"Bokemeyer\u00a0C, Kollmannsberger\u00a0C, Meisner\u00a0C, Harstrick\u00a0A, Beyer\u00a0J, Metzner\u00a0B et al (1999) First-line high-dose chemotherapy compared with standard-dose PEB\/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J\u00a0Clin Oncol 17(11):3450\u20133456. https:\/\/doi.org\/10.1200\/jco.1999.17.11.3450","journal-title":"J Clin Oncol"},{"issue":"6","key":"1831_CR15","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/bjc.1998.587","volume":"78","author":"R de Wit","year":"1998","unstructured":"de Wit\u00a0R, Stoter\u00a0G, Sleijfer\u00a0DT, Neijt\u00a0JP, ten Bokkel Huinink\u00a0WW, de Prijck\u00a0L et al (1998) Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a\u00a0randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 78(6):828\u2013832. https:\/\/doi.org\/10.1038\/bjc.1998.587","journal-title":"Br J Cancer"},{"issue":"6","key":"1831_CR16","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1200\/jco.2001.19.6.1629","volume":"19","author":"R de Wit","year":"2001","unstructured":"de Wit\u00a0R, Roberts\u00a0JT, Wilkinson\u00a0PM, de Mulder\u00a0PH, Mead\u00a0GM, Foss\u00e5\u00a0SD et al (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a\u00a03- or 5\u2011day schedule in good-prognosis germ cell cancer: a\u00a0randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J\u00a0Clin Oncol 19(6):1629\u20131640. https:\/\/doi.org\/10.1200\/jco.2001.19.6.1629","journal-title":"J Clin Oncol"},{"issue":"4","key":"1831_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/COC.0b013e31829e19e0","volume":"38","author":"BP Mulherin","year":"2015","unstructured":"Mulherin\u00a0BP, Brames\u00a0MJ, Einhorn\u00a0LH (2015) Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. Am J Clin Oncol 38(4):373\u2013376. https:\/\/doi.org\/10.1097\/COC.0b013e31829e19e0","journal-title":"Am J Clin Oncol"},{"key":"1831_CR18","volume-title":"NCCN Guidelines Version 3.2021, Hematopoietic growth factors. NCCN Clinical Practice GUIDELINES in Oncology (NCCN Guidelines)","author":"EA Griffiths","year":"2021","unstructured":"Griffiths\u00a0EA (2021) NCCN Guidelines Version 3.2021, Hematopoietic growth factors. NCCN Clinical Practice GUIDELINES in Oncology (NCCN Guidelines)"},{"key":"1831_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ejca.2020.06.001","volume":"135","author":"R Yarza","year":"2020","unstructured":"Yarza\u00a0R, Bover\u00a0M, Paredes\u00a0D, L\u00f3pez-L\u00f3pez\u00a0F, Jara-Casas\u00a0D, Castelo-Loureiro\u00a0A et al (2020) SARS-CoV\u20112 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer 135:242\u2013250. https:\/\/doi.org\/10.1016\/j.ejca.2020.06.001","journal-title":"Eur J Cancer"},{"key":"1831_CR20","unstructured":"(2021) COVID-19\u00a0patient care information\u2014cancer treatment & supportive care. https:\/\/www.asco.org\/covid-resources\/patient-care-info\/cancer-treatment-supportive-care. Zugegriffen: 31. Jan. 2022"},{"key":"1831_CR21","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7610","author":"EA Griffiths","year":"2020","unstructured":"Griffiths\u00a0EA, Alwan\u00a0LM, Bachiashvili\u00a0K, Brown\u00a0A, Cool\u00a0R, Curtin\u00a0P et al (2020) Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic. J\u00a0Natl Compr Cancer Netw. https:\/\/doi.org\/10.6004\/jnccn.2020.7610","journal-title":"J Natl Compr Cancer Netw"},{"key":"1831_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100038","author":"M Aapro","year":"2021","unstructured":"Aapro\u00a0M, Lyman\u00a0GH, Bokemeyer\u00a0C, Rapoport\u00a0BL, Mathieson\u00a0N, Koptelova\u00a0N et al (2021) Supportive care in patients with cancer during the COVID-19 pandemic. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2020.100038","journal-title":"ESMO Open"},{"key":"1831_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab534","author":"AW Zhang","year":"2021","unstructured":"Zhang\u00a0AW, Morjaria\u00a0S, Kaltsas\u00a0A, Hohl\u00a0TM, Parameswaran\u00a0R, Patel\u00a0D et al (2021) The effect of neutropenia and filgrastim (G-CSF) in cancer patients with COVID-19 infection. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciab534","journal-title":"Clin Infect Dis"},{"key":"1831_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164205","author":"M Sereno","year":"2021","unstructured":"Sereno\u00a0M, Jimenez-Gordo\u00a0AM, Baena-Espinar\u00a0J, Aguado\u00a0C, Mielgo\u00a0X, Pertejo\u00a0A et al (2021) A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 optionally treated with granulocyte-colony stimulating factor (G-CSF): a comparative analysis. Cancers. https:\/\/doi.org\/10.3390\/cancers13164205","journal-title":"Cancers"},{"issue":"17","key":"1831_CR25","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.2217\/imt-2021-0219","volume":"13","author":"A Lasagna","year":"2021","unstructured":"Lasagna\u00a0A, Muzzana\u00a0M, Pedrazzoli\u00a0P (2021) Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research. Immunotherapy 13(17):1369\u20131372. https:\/\/doi.org\/10.2217\/imt-2021-0219","journal-title":"Immunotherapy"},{"issue":"2","key":"1831_CR26","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s00520-020-05906-y","volume":"29","author":"T Cooksley","year":"2021","unstructured":"Cooksley\u00a0T, Font\u00a0C, Scotte\u00a0F, Escalante\u00a0C, Johnson\u00a0L, Anderson\u00a0R et al (2021) Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a\u00a0MASCC position paper. Support Care Cancer 29(2):1129\u20131138. https:\/\/doi.org\/10.1007\/s00520-020-05906-y","journal-title":"Support Care Cancer"},{"key":"1831_CR27","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer\u00a0NM, Dale\u00a0DC, Crawford\u00a0J, Cosler\u00a0LE, Lyman\u00a0GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258\u20132266","journal-title":"Cancer"},{"key":"1831_CR28","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith\u00a0TJ, Khatcheressian\u00a0J, Lyman\u00a0GH, Ozer\u00a0H, Armitage\u00a0JO, Balducci\u00a0L et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J\u00a0Clin Oncol 24:3187\u20133205","journal-title":"J Clin Oncol"},{"key":"1831_CR29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes\u00a0FA, O\u2019Shaughnessy\u00a0JA, Vukelja\u00a0S, Jones\u00a0SE, Shogan\u00a0J, Savin\u00a0M et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J\u00a0Clinoncol 20:727\u2013731","journal-title":"J Clinoncol"},{"issue":"6","key":"1831_CR30","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel\u00a0CL, Wojtukiewicz\u00a0MZ, Carroll\u00a0RR, Tjulandin\u00a0SA, Barajas-Figueroa\u00a0LJ, Wiens\u00a0BL et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a\u00a0multicenter, double-blind, placebo-controlled phase III study. J\u00a0Clin Oncol 23(6):1178\u20131184","journal-title":"J Clin Oncol"},{"issue":"1","key":"1831_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green\u00a0MD, Koelbl\u00a0H, Baselga\u00a0J, Galid\u00a0A, Guillem\u00a0V, Gascon\u00a0P et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14(1):29\u201335. https:\/\/doi.org\/10.1093\/annonc\/mdg019","journal-title":"Ann Oncol"},{"issue":"8","key":"1831_CR32","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/annonc\/mdl135","volume":"17","author":"M Martin","year":"2006","unstructured":"Martin\u00a0M, Lluch\u00a0A, Segui\u00a0MA, Ruiz\u00a0A, Ramos\u00a0M, Adrover\u00a0E et al (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5\u2011fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17(8):1205\u20131212","journal-title":"Ann Oncol"},{"key":"1831_CR33","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer\u00a0NM, Dale\u00a0DC, Crawford\u00a0J, Lyman\u00a0GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J\u00a0Clin Oncol 25:3158\u20133167","journal-title":"J Clin Oncol"},{"issue":"7","key":"1831_CR34","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/annonc\/mdv174","volume":"26","author":"GH Lyman","year":"2015","unstructured":"Lyman\u00a0GH, Reiner\u00a0M, Morrow\u00a0PK, Crawford\u00a0J (2015) The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. Ann Oncol 26(7):1452\u20131458. https:\/\/doi.org\/10.1093\/annonc\/mdv174","journal-title":"Ann Oncol"},{"key":"1831_CR35","unstructured":"Supportive Therapie bei onkologischen PatientInnen \u2013 Langversion 1.0, 2016, AWMF Registernummer: 032\/054OL. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Berlin: DKG, ASORS, DGHO, DEGRO. Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.\u202fV. (AWMF), Deutschen Krebsgesellschaft e.\u202fV. (DKG) und Deutschen Krebshilfe (DKH); 2016. http:\/\/leitlinienprogramm-onkologie.de\/Supportive-Therapie.95.0.html"},{"issue":"suppl 5","key":"1831_CR36","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky\u00a0J et\u00a0al (2016) Ann Oncol 27(suppl 5):v111\u2013v118","journal-title":"Ann Oncol"},{"issue":"1","key":"1831_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro\u00a0MS, Bohlius\u00a0J, Cameron\u00a0DA, Dal\u00a0LL, Donnelly\u00a0JP, Kearney\u00a0N et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332","journal-title":"Eur J Cancer"},{"key":"1831_CR38","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith\u00a0TJ et\u00a0al (2015) J\u00a0Clin Oncol 33:3199\u20133212","journal-title":"J Clin Oncol"},{"issue":"34","key":"1831_CR39","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1200\/JCO.2012.44.6229","volume":"31","author":"MJ Aarts","year":"2013","unstructured":"Aarts\u00a0MJ, Peters\u00a0FP, Mandigers\u00a0CM, Dercksen\u00a0MW, Stouthard\u00a0JM, Nortier\u00a0HJ et al (2013) Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J\u00a0Clin Oncol 31(34):4290\u20134296. https:\/\/doi.org\/10.1200\/JCO.2012.44.6229","journal-title":"J Clin Oncol"},{"issue":"3","key":"1831_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/03007995.2019.1703665","volume":"36","author":"J Edelsberg","year":"2020","unstructured":"Edelsberg\u00a0J, Weycker\u00a0D, Bensink\u00a0M, Bowers\u00a0C, Lyman\u00a0GH (2020) Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25\u00a0years. Curr Med Res Opin 36(3):483\u2013495. https:\/\/doi.org\/10.1080\/03007995.2019.1703665","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"1831_CR41","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1093\/annonc\/mdv389","volume":"26","author":"RC Leonard","year":"2015","unstructured":"Leonard\u00a0RC, Mansi\u00a0JL, Keerie\u00a0C, Yellowlees\u00a0A, Crawford\u00a0S, Benstead\u00a0K et al (2015) A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor (\u2018SPROG\u2019 trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN. Ann Oncol 26(12):2437\u20132441. https:\/\/doi.org\/10.1093\/annonc\/mdv389","journal-title":"Ann Oncol"},{"issue":"2","key":"1831_CR42","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","volume":"23","author":"AM Pfeil","year":"2015","unstructured":"Pfeil\u00a0AM, Allcott\u00a0K, Pettengell\u00a0R, von Minckwitz\u00a0G, Schwenkglenks\u00a0M, Szabo\u00a0Z (2015) Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a\u00a0systematic review. Support Care Cancer 23(2):525\u2013545. https:\/\/doi.org\/10.1007\/s00520-014-2457-z","journal-title":"Support Care Cancer"},{"key":"1831_CR43","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1185\/030079907X219599","volume":"23","author":"L Pinto","year":"2007","unstructured":"Pinto\u00a0L, Liu\u00a0Z, Doan\u00a0Q, Bernal\u00a0M, Dubois\u00a0R, Lyman\u00a0G (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a\u00a0meta-analysis of randomized controlled trials. Curr Med Res Opin 23:2283\u20132295","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"1831_CR44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/1078155217714859","volume":"24","author":"TC Bond","year":"2018","unstructured":"Bond\u00a0TC, Szabo\u00a0E, Gabriel\u00a0S, Klastersky\u00a0J, Tomey\u00a0O, Mueller\u00a0U et al (2018) Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J\u00a0Oncol Pharm Pract 24(6):412\u2013423. https:\/\/doi.org\/10.1177\/1078155217714859","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"1831_CR45","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s00520-020-05711-7","volume":"29","author":"H Link","year":"2021","unstructured":"Link\u00a0H, Illerhaus\u00a0G, Martens\u00a0UM, Salar\u00a0A, Depenbusch\u00a0R, Kohler\u00a0A et al (2021) Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Support Care Cancer 29(5):2519\u20132527. https:\/\/doi.org\/10.1007\/s00520-020-05711-7","journal-title":"Support Care Cancer"},{"issue":"3","key":"1831_CR46","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1345\/aph.1G516","volume":"40","author":"D Weycker","year":"2006","unstructured":"Weycker\u00a0D, Hackett\u00a0J, Edelsberg\u00a0JS, Oster\u00a0G, Glass\u00a0AG (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40(3):402\u2013407. https:\/\/doi.org\/10.1345\/aph.1G516","journal-title":"Ann Pharmacother"},{"issue":"2","key":"1831_CR47","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00520-016-3421-x","volume":"25","author":"D Weycker","year":"2017","unstructured":"Weycker\u00a0D, Li\u00a0X, Tzivelekis\u00a0S, Atwood\u00a0M, Garcia\u00a0J, Li\u00a0Y et al (2017) Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer 25(2):439\u2013447. https:\/\/doi.org\/10.1007\/s00520-016-3421-x","journal-title":"Support Care Cancer"},{"issue":"8","key":"1831_CR48","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1007\/s00520-017-3703-y","volume":"25","author":"GH Lyman","year":"2017","unstructured":"Lyman\u00a0GH, Allcott\u00a0K, Garcia\u00a0J, Stryker\u00a0S, Li\u00a0Y, Reiner\u00a0MT et al (2017) The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a\u00a0systematic review. Support Care Cancer 25(8):2619\u20132629. https:\/\/doi.org\/10.1007\/s00520-017-3703-y","journal-title":"Support Care Cancer"},{"key":"1831_CR49","unstructured":"European Medicines Agency, SmPC (2007) Neulasta-Pegfilgrastim. 16.7.2007, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/neulasta. Zugegriffen: 26.04.2022"},{"issue":"16","key":"1831_CR50","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2011.37.8364","volume":"30","author":"JJ Kirshner","year":"2012","unstructured":"Kirshner\u00a0JJ, Heckler\u00a0CE, Janelsins\u00a0MC, Dakhil\u00a0SR, Hopkins\u00a0JO, Coles\u00a0C et al (2012) Prevention of pegfilgrastim-induced bone pain: a\u00a0phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base. J\u00a0Clin Oncol 30(16):1974\u20131979. https:\/\/doi.org\/10.1200\/JCO.2011.37.8364","journal-title":"J Clin Oncol"},{"issue":"4","key":"1831_CR51","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00520-017-3959-2","volume":"26","author":"JJ Kirshner","year":"2018","unstructured":"Kirshner\u00a0JJ, McDonald\u00a0MC, Kruter\u00a0F, Guinigundo\u00a0AS, Vanni\u00a0L, Maxwell\u00a0CL et al (2018) NOLAN: a\u00a0randomized, phase 2\u00a0study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. Support Care Cancer 26(4):1323\u20131334. https:\/\/doi.org\/10.1007\/s00520-017-3959-2","journal-title":"Support Care Cancer"},{"key":"1831_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.08.012","author":"EM Kwan","year":"2017","unstructured":"Kwan\u00a0EM, Beck\u00a0S, Amir\u00a0E, Jewett\u00a0MA, Sturgeon\u00a0JF, Anson-Cartwright\u00a0L et al (2017) Impact of granulocyte-colony stimulating factor on bleomycin-induced pneumonitis in chemotherapy-treated germ cell tumors. Clin Genitourin Cancer. https:\/\/doi.org\/10.1016\/j.clgc.2017.08.012","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"1831_CR53","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1177\/1078155218804293","volume":"25","author":"M Laprise-Lachance","year":"2019","unstructured":"Laprise-Lachance\u00a0M, Lemieux\u00a0P, Gr\u00e9goire\u00a0JP (2019) Risk of pulmonary toxicity of bleomycin and filgrastim. J\u00a0Oncol Pharm Pract 25(7):1638\u20131644. https:\/\/doi.org\/10.1177\/1078155218804293","journal-title":"J Oncol Pharm Pract"},{"key":"1831_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.770067","author":"R Nakagawa","year":"2022","unstructured":"Nakagawa\u00a0R, Iwamoto\u00a0H, Makino\u00a0T, Kadomoto\u00a0S, Yaegashi\u00a0H, Iijima\u00a0M et\u00a0al (2022) Analysis of the safety of pegfilgrastim addition in bleomycin, etoposide, and cisplatin treatment patients with germ cell tumors. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.770067","journal-title":"Front Oncol"},{"issue":"4","key":"1831_CR55","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/10428194.2018.1515939","volume":"60","author":"MD Andersen","year":"2019","unstructured":"Andersen\u00a0MD, Kamper\u00a0P, d\u2019Amore\u00a0A, Clausen\u00a0M, Bentzen\u00a0H, d\u2019Amore\u00a0F (2019) The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45\u00a0years exposed to granulocyte-colony stimulating growth factor. Leuk Lymphoma 60(4):927\u2013933. https:\/\/doi.org\/10.1080\/10428194.2018.1515939","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 7A","key":"1831_CR56","doi-asserted-by":"publisher","first-page":"11S","DOI":"10.1016\/j.amjmed.2003.12.008","volume":"116","author":"K Knight","year":"2004","unstructured":"Knight\u00a0K, Wade\u00a0S, Balducci\u00a0L (2004) Prevalence and outcomes of anemia in cancer: a\u00a0systematic review of the literature. Am J Med 116(Suppl 7A):11S\u201326S. https:\/\/doi.org\/10.1016\/j.amjmed.2003.12.008","journal-title":"Am J Med"},{"issue":"5","key":"1831_CR57","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000350306","volume":"36","author":"H Link","year":"2013","unstructured":"Link\u00a0H, Schmitz\u00a0S (2013) Treatment of cancer-associated anaemia: results from a\u00a0two-day cross-sectional survey in Germany. Onkologie 36(5):266\u2013272. https:\/\/doi.org\/10.1159\/000350306","journal-title":"Onkologie"},{"issue":"10","key":"1831_CR58","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra041809","volume":"352","author":"G Weiss","year":"2005","unstructured":"Weiss\u00a0G, Goodnough\u00a0LT (2005) Anemia of chronic disease. N\u00a0Engl J Med 352(10):1011\u20131023. https:\/\/doi.org\/10.1056\/NEJMra041809","journal-title":"N Engl J Med"},{"issue":"24","key":"1831_CR59","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJM199006143222401","volume":"322","author":"CB Miller","year":"1990","unstructured":"Miller\u00a0CB, Jones\u00a0RJ, Piantadosi\u00a0S, Abeloff\u00a0MD, Spivak\u00a0JL (1990) Decreased erythropoietin response in patients with the anemia of cancer. N\u00a0Engl J Med 322(24):1689\u20131692. https:\/\/doi.org\/10.1056\/NEJM199006143222401","journal-title":"N Engl J Med"},{"key":"1831_CR60","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1182\/blood-2011-01-258467","volume":"117","author":"T Ganz","year":"2011","unstructured":"Ganz\u00a0T (2011) Hepcidin and iron regulation, 10\u00a0years later. Blood 117:4425\u20134433","journal-title":"Blood"},{"issue":"12","key":"1831_CR61","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1056\/NEJMra1804281","volume":"381","author":"T Ganz","year":"2019","unstructured":"Ganz\u00a0T (2019) Anemia of Inflammation. N\u00a0Engl J Med 381(12):1148\u20131157. https:\/\/doi.org\/10.1056\/NEJMra1804281","journal-title":"N Engl J Med"},{"key":"1831_CR62","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00277-007-0258-x","volume":"86","author":"E Katodritou","year":"2007","unstructured":"Katodritou\u00a0E, Terpos\u00a0E, Zervas\u00a0K, Speletas\u00a0M, Kapetanos\u00a0D, Kartsios\u00a0C et al (2007) Hypochromic erythrocytes (%): a\u00a0reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol 86:369\u2013376","journal-title":"Ann Hematol"},{"issue":"7","key":"1831_CR63","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","volume":"22","author":"M Auerbach","year":"2004","unstructured":"Auerbach\u00a0M, Ballard\u00a0H, Trout\u00a0JR, McIlwain\u00a0M, Ackerman\u00a0A, Bahrain\u00a0H et al (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a\u00a0multicenter, open-label, randomized trial. J\u00a0Clin Oncol 22(7):1301\u20131307","journal-title":"J Clin Oncol"},{"issue":"4","key":"1831_CR64","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1093\/ndt\/gfl765","volume":"22","author":"C Bovy","year":"2007","unstructured":"Bovy\u00a0C, Gothot\u00a0A, Delanaye\u00a0P, Warling\u00a0X, Krzesinski\u00a0JM, Beguin\u00a0Y (2007) Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity. Nephrol Dial Transplant 22(4):1156\u20131162","journal-title":"Nephrol Dial Transplant"},{"key":"1831_CR65","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","volume":"19","author":"TJ Littlewood","year":"2001","unstructured":"Littlewood\u00a0TJ, Bajetta\u00a0E, Nortier\u00a0JW, Vercammen\u00a0E, Rapoport\u00a0B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a\u00a0randomized, double-blind, placebo-controlled trial. J\u00a0Clin Oncol 19:2865\u20132874","journal-title":"J Clin Oncol"},{"issue":"12","key":"1831_CR66","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1200\/JCO.2004.10.020","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig\u00a0TE, Silberstein\u00a0PT, Loprinzi\u00a0CL, Sloan\u00a0JA, Novotny\u00a0PJ, Mailliard\u00a0JA et al (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J\u00a0Clin Oncol 23(12):2606\u20132617","journal-title":"J Clin Oncol"},{"key":"1831_CR67","unstructured":"Querschnitts-Leitlinien BAEK zur Therapie mit Blutkomponenten und Plasmaderivaten-Gesamtnovelle 2020. Berlin: Bundes\u00e4rztekammer; 2020."},{"key":"1831_CR68","volume-title":"H\u00e4movigilanz-Bericht des Paul-Ehrlich-Instituts 2019: Auswertung der Meldungen von Reaktionen und Zwischenf\u00e4llen nach \u00a7 63i AMG","author":"MB Funk","year":"2021","unstructured":"Funk\u00a0MB, Heiden\u00a0M, M\u00fcller\u00a0S et al (2021) H\u00e4movigilanz-Bericht des Paul-Ehrlich-Instituts 2019: Auswertung der Meldungen von Reaktionen und Zwischenf\u00e4llen nach \u00a7 63i AMG"},{"issue":"1","key":"1831_CR69","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/asheducation-2013.1.638","volume":"2013","author":"ZM Szczepiorkowski","year":"2013","unstructured":"Szczepiorkowski\u00a0ZM, Dunbar\u00a0NM (2013) Transfusion guidelines: when to transfuse. ASH Educ Program Book 2013(1):638\u2013644. https:\/\/doi.org\/10.1182\/asheducation-2013.1.638","journal-title":"ASH Educ Program Book"},{"issue":"24","key":"1831_CR70","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1182\/blood-2013-07-518423","volume":"122","author":"LK Hicks","year":"2013","unstructured":"Hicks\u00a0LK, Bering\u00a0H, Carson\u00a0KR, Kleinerman\u00a0J, Kukreti\u00a0V, Ma\u00a0A et\u00a0al (2013) The ASH Choosing Wisely(R) campaign: five hematologic tests and treatments to question. Blood 122(24):3879\u20133883. https:\/\/doi.org\/10.1182\/blood-2013-07-518423","journal-title":"Blood"},{"key":"1831_CR71","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.67.7377","author":"I Gross","year":"2016","unstructured":"Gross\u00a0I, Farmer\u00a0S, Hofmann\u00a0A, Ozawa\u00a0S, Shander\u00a0A, Aapro\u00a0M (2016) Critical role of iron in epoetin alfa treatment of chemotherapy-associated anemia. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2016.67.7377","journal-title":"J Clin Oncol"},{"issue":"9800","key":"1831_CR72","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S0140-6736(11)61381-0","volume":"378","author":"KM Musallam","year":"2011","unstructured":"Musallam\u00a0KM, Tamim\u00a0HM, Richards\u00a0T, Spahn\u00a0DR, Rosendaal\u00a0FR, Habbal\u00a0A et al (2011) Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a\u00a0retrospective cohort study. Lancet 378(9800):1396\u20131407","journal-title":"Lancet"},{"key":"1831_CR73","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1056\/NEJM199902113400601","volume":"340","author":"PC Hebert","year":"1999","unstructured":"Hebert\u00a0PC, Wells\u00a0G, Blajchman\u00a0MA, Marshall\u00a0J, Martin\u00a0C, Pagliarello\u00a0G et\u00a0al (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N\u00a0Engl J Med 340:409\u2013417","journal-title":"N Engl J Med"},{"key":"1831_CR74","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1211801","volume":"368","author":"C Villanueva","year":"2013","unstructured":"Villanueva\u00a0C, Colomo\u00a0A, Bosch\u00a0A, Concepcion\u00a0M, Hernandez-Gea\u00a0V, Aracil\u00a0C et al (2013) Transfusion strategies for acute upper gastrointestinal bleeding. N\u00a0Engl J Med 368:11\u201321","journal-title":"N Engl J Med"},{"issue":"5","key":"1831_CR75","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000511229","volume":"47","author":"T Tomic Mahecic","year":"2020","unstructured":"Tomic Mahecic\u00a0T, D\u00fcnser\u00a0M, Meier\u00a0J (2020) RBC transfusion triggers: is there anything new? Transfus Med Hemother 47(5):361\u2013369. https:\/\/doi.org\/10.1159\/000511229","journal-title":"Transfus Med Hemother"},{"key":"1831_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002042.pub4","author":"JL Carson","year":"2016","unstructured":"Carson\u00a0JL, Stanworth\u00a0SJ, Roubinian\u00a0N, Fergusson\u00a0DA, Triulzi\u00a0D, Doree\u00a0C et\u00a0al (2016) Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD002042.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"1831_CR77","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1056\/NEJMoa1012452","volume":"365","author":"JL Carson","year":"2011","unstructured":"Carson\u00a0JL, Terrin\u00a0ML, Noveck\u00a0H, Sanders\u00a0DW, Chaitman\u00a0BR, Rhoads\u00a0GG et al (2011) Liberal or restrictive transfusion in high-risk patients after hip surgery. N\u00a0Engl J Med 365:2453\u20132462","journal-title":"N Engl J Med"},{"issue":"2","key":"1831_CR78","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.amjmed.2013.09.017","volume":"127","author":"SR Salpeter","year":"2014","unstructured":"Salpeter\u00a0SR, Buckley\u00a0JS, Chatterjee\u00a0S (2014) Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review. Am J Med 127(2):124\u2013131.e3. https:\/\/doi.org\/10.1016\/j.amjmed.2013.09.017","journal-title":"Am J Med"},{"key":"1831_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005033.pub2","author":"A Amato","year":"2006","unstructured":"Amato\u00a0A, Pescatori\u00a0M (2006) Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD005033.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1831_CR80","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1537-2995.2010.02825.x","volume":"51","author":"FV Mortensen","year":"2011","unstructured":"Mortensen\u00a0FV, Jensen\u00a0LS, S\u00f6rensen\u00a0HT, Pedersen\u00a0L (2011) Cause-specific mortality associated with leukoreduced, buffy coat\u2013depleted, or no blood transfusion after elective surgery for colorectal cancer: a\u00a0posttrial 15-year follow-up study. Transfusion 51:259\u2013263","journal-title":"Transfusion"},{"key":"1831_CR81","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1182\/blood-2010-03-276683","volume":"116","author":"JJ Castillo","year":"2010","unstructured":"Castillo\u00a0JJ, Dalia\u00a0S, Pascual\u00a0SK (2010) Association between red blood cell transfusions and development of non-hodgkin lymphoma: a\u00a0meta-analysis of observational studies. Blood 116:2897\u20132907","journal-title":"Blood"},{"key":"1831_CR82","unstructured":"Meybohm PZ (2021) Kai: patient blood managment. https:\/\/www.patientbloodmanagement.de\/. Zugegriffen: 27. Nov. 2021"},{"issue":"6","key":"1831_CR83","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/trf.14006","volume":"57","author":"MF Leahy","year":"2017","unstructured":"Leahy\u00a0MF, Hofmann\u00a0A, Towler\u00a0S, Trentino\u00a0KM, Burrows\u00a0SA, Swain\u00a0SG et al (2017) Improved outcomes and reduced costs associated with a\u00a0health-system-wide patient blood management program: a\u00a0retrospective observational study in four major adult tertiary-care hospitals. Transfusion 57(6):1347\u20131358. https:\/\/doi.org\/10.1111\/trf.14006","journal-title":"Transfusion"},{"issue":"Suppl 4","key":"1831_CR84","doi-asserted-by":"publisher","first-page":"iv96","DOI":"10.1093\/annonc\/mdx758","volume":"29","author":"M Aapro","year":"2018","unstructured":"Aapro\u00a0M, Beguin\u00a0Y, Bokemeyer\u00a0C, Dicato\u00a0M, Gascon\u00a0P, Glaspy\u00a0J et\u00a0al (2018) Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. Ann Oncol 29(Suppl 4):iv96\u2013iv110. https:\/\/doi.org\/10.1093\/annonc\/mdx758","journal-title":"Ann Oncol"},{"key":"1831_CR85","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","volume":"122","author":"M Hedenus","year":"2003","unstructured":"Hedenus\u00a0M, Adriansson\u00a0M, San\u00a0MJ, Kramer\u00a0MH, Schipperus\u00a0MR, Juvonen\u00a0E et al (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a\u00a0randomized, double-blind, placebo-controlled study. Br J Haematol 122:394\u2013403","journal-title":"Br J Haematol"},{"issue":"12","key":"1831_CR86","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1200\/JCO.2004.12.027","volume":"23","author":"J Chang","year":"2005","unstructured":"Chang\u00a0J, Couture\u00a0F, Young\u00a0S, McWatters\u00a0KL, Lau\u00a0CY (2005) Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J\u00a0Clin Oncol 23(12):2597\u20132605","journal-title":"J Clin Oncol"},{"key":"1831_CR87","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ejca.2006.10.014","volume":"43","author":"C Bokemeyer","year":"2007","unstructured":"Bokemeyer\u00a0C, Aapro\u00a0MS, Courdi\u00a0A, Foubert\u00a0J, Link\u00a0H, Osterborg\u00a0A et\u00a0al (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43:258\u2013270","journal-title":"Eur J Cancer"},{"issue":"1","key":"1831_CR88","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tmrv.2005.08.002","volume":"20","author":"HL Corwin","year":"2006","unstructured":"Corwin\u00a0HL (2006) The role of erythropoietin therapy in the critically ill. Transfus Med Rev 20(1):27\u201333","journal-title":"Transfus Med Rev"},{"key":"1831_CR89","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/jnci\/94.16.1211","volume":"94","author":"J Vansteenkiste","year":"2002","unstructured":"Vansteenkiste\u00a0J, Pirker\u00a0R, Massuti\u00a0B, Barata\u00a0F, Font\u00a0A, Fiegl\u00a0M et al (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J\u00a0Natl Cancer Inst 94:1211\u20131220","journal-title":"J Natl Cancer Inst"},{"key":"1831_CR90","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2006.10.4620","volume":"26","author":"L Bastit","year":"2008","unstructured":"Bastit\u00a0L, Vandebroek\u00a0A, Altintas\u00a0S, Gaede\u00a0B, Pinter\u00a0T, Suto\u00a0TS et al (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J\u00a0Clin Oncol 26:1611\u20131618","journal-title":"J Clin Oncol"},{"issue":"1","key":"1831_CR91","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/bjc.2014.171","volume":"111","author":"J Bohlius","year":"2014","unstructured":"Bohlius\u00a0J, Tonia\u00a0T, Nuesch\u00a0E, Juni\u00a0P, Fey\u00a0MF, Egger\u00a0M et al (2014) Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Br J Cancer 111(1):33\u201345. https:\/\/doi.org\/10.1038\/bjc.2014.171","journal-title":"Br J Cancer"},{"issue":"15","key":"1831_CR92","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1200\/JCO.18.02142","volume":"37","author":"J Bohlius","year":"2019","unstructured":"Bohlius\u00a0J, Bohlke\u00a0K, Castelli\u00a0R, Djulbegovic\u00a0B, Lustberg\u00a0MB, Martino\u00a0M et al (2019) Management of cancer-associated anemia with erythropoiesis-stimulating agents: aSCO\/ASH clinical practice guideline update. J\u00a0Clin Oncol 37(15):1336\u20131351. https:\/\/doi.org\/10.1200\/JCO.18.02142","journal-title":"J Clin Oncol"},{"key":"1831_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003407.pub5","author":"T Tonia","year":"2012","unstructured":"Tonia\u00a0T, Mettler\u00a0A, Robert\u00a0N, Schwarzer\u00a0G, Seidenfeld\u00a0J, Weingart\u00a0O et\u00a0al (2012) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD003407.pub5","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1831_CR94","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood.V96.3.823","volume":"96","author":"LT Goodnough","year":"2000","unstructured":"Goodnough\u00a0LT, Skikne\u00a0B, Brugnara\u00a0C (2000) Erythropoietin, iron, and erythropoiesis. Blood 96(3):823\u2013833","journal-title":"Blood"},{"key":"1831_CR95","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1200\/JCO.2010.30.3644","volume":"29","author":"DP Steensma","year":"2011","unstructured":"Steensma\u00a0DP, Sloan\u00a0JA, Dakhil\u00a0SR, Dalton\u00a0R, Kahanic\u00a0SP, Prager\u00a0DJ et al (2011) Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J\u00a0Clin Oncol 29:97\u2013105","journal-title":"J Clin Oncol"},{"issue":"17","key":"1831_CR96","doi-asserted-by":"publisher","first-page":"e525","DOI":"10.1200\/JCO.2011.35.3219","volume":"29","author":"M Aapro","year":"2011","unstructured":"Aapro\u00a0M, Beguin\u00a0Y, Birgegard\u00a0G, Gascon\u00a0P, Hedenus\u00a0M, Osterborg\u00a0A (2011) Too-low iron doses and too many dropouts in negative iron trial? J\u00a0Clin Oncol 29(17):e525\u2013e526. https:\/\/doi.org\/10.1200\/JCO.2011.35.3219 (author reply e7\u20138)","journal-title":"J Clin Oncol"},{"issue":"1","key":"1831_CR97","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3109\/0284186X.2012.702921","volume":"52","author":"A Gafter-Gvili","year":"2013","unstructured":"Gafter-Gvili\u00a0A, Rozen-Zvi\u00a0B, Vidal\u00a0L, Leibovici\u00a0L, Vansteenkiste\u00a0J, Gafter\u00a0U et\u00a0al (2013) Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia\u2014systematic review and meta-analysis of randomised controlled trials. Acta Oncol 52(1):18\u201329. https:\/\/doi.org\/10.3109\/0284186X.2012.702921","journal-title":"Acta Oncol"}],"updated-by":[{"DOI":"10.1007\/s00120-023-02037-0","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000}}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-022-01831-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-022-01831-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-022-01831-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T06:19:17Z","timestamp":1675145957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-022-01831-6"}},"subtitle":["Supportivtherapieleitlinien, Teil 1","Guidelines on supportive treatment part\u00a01"],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1831"],"URL":"https:\/\/doi.org\/10.1007\/s00120-022-01831-6","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"6 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00120-023-02037-0","URL":"https:\/\/doi.org\/10.1007\/s00120-023-02037-0","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>H.\u00a0Link<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Studienleitung MMF GmbH Dortmund\/M\u00fcnster. \u2013\u00a0Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Astellas, Amgen, Chugai Pharma Marketing Ltd., Hogg Robinson Germany GmbH & Co. KG, Mundipharma, SAP, Takeda\/Shire, Teva, Viatris\/Mylan, Vifor, Vision Plus Mailand.\u00a0\u2013 Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: Berater\u2011, Gutachtert\u00e4tigkeit, wissenschaftliches Advisory Board, Fortbildungsprojekte, Gutachter | ACCORD HEALTCARE LIMITED, Apogepha, Europharma, G1 Therapeutics, Hexal, Accord Deutschland, Johnson & Johnson, Lindis Blood Care, Mundipharma, onkowissen.de, Pharmacosmos, Servier Deutschland GmbH, Shire Deutschland GmbH Takeda Group, SIGAL SMS GmbH, Strategen Limited, Samsung Bioepis, Takeda, Viatris. \u2013\u00a0Patente, Gesch\u00e4ftsanteile, Aktien o.\u202f\u00c4. an einer im Medizinbereich aktiven Firma: Onkopti, Therapieprotokolldatenbank, Onkodin GmbH.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: ehem. Chefarzt Westpfalz-Klinikum, H\u00e4matologie, Internistische Onkologie, Stammzelltransplantation, Akademisches Lehrkrankenhaus der Universit\u00e4ten Mainz und Heidelberg, Sprechstunde f\u00fcr H\u00e4matologie und internistische Onkologie Kaiserslautern, Ethikkommission Landes\u00e4rztekammer Rheinland-Pfalz, | Deutsche Krebsgesellschaft (DKG), Arbeitsgemeinschaft Internistische Onkologie (AIO), Leitung der AG Supportivtherapie, Leitung der AG Digitalisierung, Arbeitsgemeinschaft Supportive Ma\u00dfnahmen in der Onkologie (AGSMO), Mitglied des Leitungsgremiums, Sekret\u00e4r des Onkologischen Zentrums Westpfalz (OZW), Vorsitzender des F\u00f6rdervereins Mama-Papa-hat-Krebs Kaiserslautern.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}